MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients
A research team based at the National Eye Institute, National Institutes of Health, Bethesda, Maryland, has published long-term visual outcomes for patients participating with an… Read More »A real-world study on an AI-enabled tele-monitoring project shows significant impact on long-term outcomes.
Researches based in the Centre for Ophthalmology, Eberhard Karls University of Tübingen, Germany, has reported the natural course of disease progression, with respect to central… Read More »Genotype-Phenotype correlations in PDE6A associated with arRP shows the range of severity
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 10th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 10th, 2022 “EURETINA-Brief”© Issue No. 254
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***